Skip to main content
Top
Published in: memo - Magazine of European Medical Oncology 2/2018

01-06-2018 | editorial

Laboratory diagnostics in hematology—a new “Educational” series

Author: Gerald Webersinke, PhD

Published in: memo - Magazine of European Medical Oncology | Issue 2/2018

Login to get access

Excerpt

Correct diagnosis in hemato-oncology can be a challenge even for the specialist: in the new WHO classification, nearly 200 entities are defined based on different biological and clinical characteristics [1]. With the advent of massive parallel sequencing, the knowledge about the genetic landscape of diverse diseases expanded dramatically over a few years; an example is acute myeloid leukemia, where dozens of subgroups according to specific genetic changes can be differentiated [2]. This resulted in new prognostic models and therapeutic opportunities; however, the overwhelming amount of diagnostic (often genetic) information may leave even the specialist clueless. Therefore, it is clear that the diagnostic process in hemato-oncology needs to be multidisciplinary and interactive to achieve a correct result for optimal patient care. …
Literature
1.
go back to reference Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: lARC; 2017. ISBN 978-9283244943. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: lARC; 2017. ISBN 978-9283244943.
2.
go back to reference Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.CrossRefPubMedPubMedCentral Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.CrossRefPubMedPubMedCentral
Metadata
Title
Laboratory diagnostics in hematology—a new “Educational” series
Author
Gerald Webersinke, PhD
Publication date
01-06-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0399-8

Other articles of this Issue 2/2018

memo - Magazine of European Medical Oncology 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine